Navigation Links
Experimental gene therapy treatment for Duchenne muscular dystrophy offers hope for youngster
Date:2/7/2013

hin in the participants' muscles the latter results obtained through muscle biopsies at several times during study. Of particular interest to the research teams are the residual effects of the drug several weeks after the injection series is completed.

Although McDonald says it is too early to draw conclusions from the current clinical trial, he suggests there is reason to be optimistic based on animal studies and evidence from another clinical trial in Europe. In that trial, patients and study investigators knew which patients were actually taking the experimental drug, meaning it was an "open" study. The current U.S. study is more rigorous because doctors and families are "blinded" about which drug regimen each participant has -- either one of two dosages of the drug or a placebo -- until the end of the study.

According to McDonald, the antisense oligonucleotide-mediated genetic therapy approach is particularly exciting because of its potential applications to most other variants of Duchenne muscular dystrophy and other genetic diseases. Although the current experimental therapy specifically addresses mutations in only one particular region of the gene, the same therapeutic concept can be applied to many others.

"If successful, this approach can be developed into specific gene therapy that represents truly personalized medicine," said McDonald. "Covering a mutation to restore a normal genetic open reading frame for protein synthesis can be a powerful approach for a variety of genetic diseases."

Standardizing the drug as a therapy for Duchenne patients still requires approval by the U.S. Food and Drug Administration. Investigators say the therapy could be similar to insulin injections for diabetes. But rather than daily injections, the Duchenne treatment might only involve weekly shots, which youngsters could learn to administer on their own.

Now that the clinical trial is closed at UC Davis to new enrollees, McDonald
'/>"/>

Contact: Charles Casey
charles.casey@ucdmc.ucdavis.edu
916-734-9048
University of California - Davis Health System
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Experimental drug combination selectively destroys lymphoma cells
2. Nicole George wins 2012 Journal of Experimental Biology Outstanding Paper Prize
3. Compound stimulates tumor-fighting protein in cancer therapy
4. VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013
5. Pitt researchers reveal mechanism to halt cancer cell growth, discover potential therapy
6. Changes to DNA on-off switches affect cells ability to repair breaks, respond to chemotherapy
7. BUSM study shows potential of differentiated iPS cells in cell therapy without immune rejection
8. Canada launches first gene therapy trial for Fabry disease
9. New way to kill lymphoma without chemotherapy
10. Gene therapy reprograms scar tissue in damaged hearts into healthy heart muscle
11. New whole plant therapy shows promise as an effective and economical treatment for malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/2/2015)... 2, 2015 According to preliminary ... to somewhat higher than 125 MSEK. This exceeds the ... 2014 that revenues for Q1 2015 would be in ... for Q4 2014. The operating result for the first ... complete interim report will as previously communicated be published ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... , SAN FRANCISCO, CAFebruary 9, 2014Sometimes biology is cruel. ... code is the difference between health and a deadly ... studied disorders caused by these tiny changes, replicating them ... But now, scientists at the Gladstone Institutes have found ...
... regions associated with type 2 diabetes have been identified ... basis of the disease. DNA data was brought ... controls from four different ethnic groups. The research was ... countries on four continents, co-led by investigators from Oxford ...
... reaction usually is "Eww," but when they see a ... Why some animals use noxious scents while others ... is the question that biologists Tim Caro of the ... State University, Long Beach and sought to answer ...
Cached Biology News:Genome editing goes hi-fi 2Genome editing goes hi-fi 3Seven new genetic regions linked to type 2 diabetes 2Social or stinky? New study reveals how animal defenses evolve 2
(Date:4/24/2015)... April 24, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... biosimilar therapeutics including high value and difficult to manufacture ... offering of 6,000,000 shares of its common stock at ... Of the shares being offered, 2,610,000 are being offered ... offered by existing stockholders. Pfenex will not receive any ...
(Date:4/24/2015)... 24, 2015  Navitas Life Sciences is delighted to announce ... Clinical and Regulatory Services. Shalabh is a proven leader in ... CEO of Kinapse, as well as a Strategy consultant at ... - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... "I am delighted to welcome Shalabh into this critical role ...
(Date:4/24/2015)... 2015 Seoul Semiconductor announced the ... applications in the lighting market. In recent ... this technology in emerging markets such as Russia, ... range of applications such as streetlight and area ... , First launched in 2005 the Acrich technology ...
(Date:4/23/2015)... (PRWEB) April 23, 2015 Athena San ... development of executive women in San Diego’s technology and ... 17th Annual Pinnacle Awards at their Gala on April ... Hotel. Register now at http://athenasd.org/events/ , The ... the Athena San Diego vision of fostering networking, risk ...
Breaking Biology Technology:Pfenex Inc. Announces Pricing Of Follow-on Offering 2Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2Athena Pinnacle Awards to Honor Executives, Corporations and Educators Working to Promote Women Leaders 2
... 28, 2011 Nature,s Bioceuticals, a wholly owned subsidiary ... billion market chronic obstructive pulmonary disease market (COPD) with ... This all natural, non-synthetic, medicine was developed for the ... which are Emphysema and Chronic Bronchitis. We believe that ...
... at the Georgia Institute of Technology have developed a ... a key ingredient found in many explosives. ... on paper or paper-like material using standard inkjet technology, ... to the presence of explosives, such as improvised explosive ...
... Halozyme Therapeutics, Inc. (NASDAQ: HALO ), a ... extracellular matrix for the diabetes, cancer, dermatology and ... to Halozyme,s clinical stage drug, pegylated rHuPH20 (PEGPH20). The ... on "Molecular Markers in Cancer", taking place October 27-29 ...
Cached Biology Technology:Nature's Bioceuticals Enters Chronic Obstructive Pulmonary Disease Market After Acquiring Breakthrough Breathing Formula 2Nature's Bioceuticals Enters Chronic Obstructive Pulmonary Disease Market After Acquiring Breakthrough Breathing Formula 3Low-cost paper-based wireless sensor could help detect explosive devices 2Low-cost paper-based wireless sensor could help detect explosive devices 3Low-cost paper-based wireless sensor could help detect explosive devices 4Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma 2Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma 3
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Use the DUALmembrane kit 3 to carry out DUALmembrane interaction analysis and cDNA library screening to characterize interactions between integral membrane proteins and to identify novel interaction ...
... effectively seals labware. Waterproof, moisture-proof film ... materials. Can be folded repeatedly and ... Stretched lengthwise at 21C (70F), wrapping ... tension is removed, film only partially ...
Biology Products: